Skip To Content

Sharing perspectives leads to greater understanding and fuels innovation.

The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.

July 20, 2021 · Public Policy & Regulatory Affairs Team
Brief updates on several recent policy developments across the country. Read more...
June 29, 2021 · Policy Matters team
Listed below are brief updates on several recent policy developments across the country. Read more...
June 25, 2021 · Public Policy & Regulatory Affairs Team
As we emerge from the COVID-19 pandemic, Post-Traumatic Stress Disorder (PTSD) presumption coverage for first responders and other “essential” workers continues to be a popular topic during the 2021 legislative season. Read more...
June 09, 2021 · Policy Matters team
Listed below are brief updates on several recent policy developments across the country. Read more...
May 25, 2021 · Public Policy & Regulatory Affairs Team
On May 24, 2021 the New York Workers’ Compensation Board (WCB) announced a delay of OnBoard-Limited Release via bulletin 046-1408. Read more...
May 18, 2021 · Policy Matters team
Listed below are brief updates on several recent policy developments across the country. Read more...
May 12, 2021 · Clinical Team
The U.S. Food and Drug Administration (FDA) approved a higher-dose naloxone hydrochloride nasal spray – Kloxxado™ (8 mg) – on April 30, 2021. Naloxone is indicated for the emergency treatment of known or suspected opioid analgesic overdose, as manifested by respiratory and/or central nervous system (CNS) depression, for adults and pediatric patients. Read more...
May 06, 2021 · Clinical Team
Pregabalin extended-release (ER) tablets, the generic formulation of Lyrica® CR, was released on April 13, 2021, according to the U.S. Food and Drug Administration (FDA). Read more...
<< Previous      Next >>
Page 2 of 19

Subscribe today to receive our latest blogs, articles, podcasts and more.